NEXIUM 40 mg and 20 mg are indicated for short-term treatment (4 to 8 weeks) in healing and symptomatic resolution of diagnostically confirmed erosive esophagitis (EE). NEXIUM 20 mg is indicated to maintain symptom resolution and healing of EE (controlled studies did not extend beyond 6 months), and for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD.
NEXIUM I.V. for injection is indicated for the short-term treatment of GERD with erosive esophagitis (EE) in adults and pediatric patients 1 month to 17 years, inclusively as an alternative to oral therapy when oral NEXIUM is not possible or appropriate.
NEXIUM I.V. for injection is indicated for risk reduction of rebleeding in patients following therapeutic endoscopy for acute bleeding gastric ulcers in adults.
Prescribing Information with Medication Guide for NEXIUM. (PDF - 303 KB)
Prescribing Information for NEXIUM I.V. (PDF - 72 KB)
You may report side effects related to AstraZeneca products by clicking here.
FlagThis product information is intended for US Health Care Professionals only.
NEXIUM and the color purple as applied to the capsule are registered trademarks of the AstraZeneca group of companies.
Fingertip Formulary is a registered trademark of Fingertip Formulary, LLC.
©2019 AstraZeneca. All rights reserved. 800808-2808500 Last approved: 9/13